Skip to main content

Table 1 Gadolinium content in the nervous system

From: Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?

 

28 days post-treatment

56 days post-treatment

 

Group

GBCA

  

Cerebrum (nmol Gd/g)

 SN rats

1

Gadoteridol

0.304 ± 0.088b2,c3,c4

0.132 ± 0.022b2,c3,c4

n

8

8

2

Gadobutrol

0.57 ± 0.12b1,c4

0.348 ± 0.097b1,c4

n

8

7

3

Gadoterate

0.554 ± 0.074c1,c4

0.321 ± 0.064c1,c4

n

8

7

 Healthy rats

4

Gadoteridol

0.087 ± 0.015c1,c2,c3

0.053 ± 0.007c1,c2,c3

n

5

5

Cerebellum (nmol Gd/g)

 SN rats

1

Gadoteridol

0.328 ± 0.081b2,b3

0.264 ± 0.094b4

n

8

8

2

Gadobutrol

0.66 ± 0.23b1,c4

0.36 ± 0.10b4

n

8

7

3

Gadoterate

0.63 ± 0.13b1,c4

0.278 ± 0.036c4

n

8

7

 Healthy rats

4

Gadoteridol

0.16 ± 0.1c2,c3

0.084 ± 0.022b1,b2,c3

n

5

5

Peripheral nerves (nmol Gd/g)

 SN rats

1

Gadoteridol

0.60 ± 0.29c2,c3,a4

0.166 ± 0.23a3

n

8

7

2

Gadobutrol

3.24 ± 0.81c1,c4

0.45 ± 0.22

n

7

6

3

Gadoterate

4.3 ± 1.4c1,c4

0.78 ± 0.58a1,c4

n

8

8

 Healthy rats

4

Gadoteridol

0.197 ± 0.035a1,c2,c3

0.114 ± 0.028c3

n

5

5

  1. Values presented as mean ± SD
  2. ap < 0.05; bp < 0.01; cp < 0.001. The number after the letter of the significance level indicates the group versus which there is a difference. See main text for actual p values